ReviewFrontiers in endocrinology2023
The obesogenic side of Genistein.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Ganoderic acid A accelerates osteoporotic fracture healing by promoting osteogenic differentiation via estrogen receptor alpha binding.Journal of orthopaedic translation · 2026Article
- Transmission of an environmental modification in quails across three generations: changes in the contribution to phenotypic variability.Genetics, selection, evolution : GSE · 2026Article
- Preparation and Evaluation of NiosomalScientifica · 2026Article
- The role of endocrine-disrupting chemicals in obesity: mechanisms, evidence, and public health implications.Frontiers in endocrinology · 2026Review
- Genistein in polycystic ovary syndrome: mechanisms, preclinical evidence, and translational potential.Frontiers in global women's health · 2026Review
- Comparative Analysis of Food Addiction and Obesity: A Critical Review.Food science & nutrition · 2025Review
- Screening the effects of phytoestrogens on lipid metabolism in primary cultured adipocytes from rainbow trout (Oncorhynchus mykiss) and gilthead sea bream (Sparus aurata).Fish physiology and biochemistry · 2025Article
- Relationship of serum irisin levels, physical activity, and metabolic syndrome biomarkers in obese individuals with low-calorie intake and non-obese individuals with high-calorie intake.Journal of health, population, and nutrition · 2025Article
- Safety and effects of scorpion-derived antimicrobial peptides as an alternative to antibiotic growth promoters in broilers: growth performance, immune function, and intestinal development.Frontiers in veterinary science · 2025Article
- Health-promoting compounds inHeliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genistein (GN) has been highly recommended for its medicinal properties like anticancer, antidiabetic, antihyperlipidemic, antiviral, and antioxidant activities among others. Recently, scientists realized that Genistein is an endocrine disruptor. It is an obesogen that interferes with the endocrine system causing obesity through many mechanisms like inducing adipocyte differentiation, lipid accumulation, and transformation of some stem cells into adipocytes (bone marrow mesenchymal stem cells for example)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.